Vertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital
RBC Capital raised the firm's price target on Vertex Pharmaceuticals to $570 from $543 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to th